Sushil Kumar Selected Research

Triple Negative Breast Neoplasms

11/2021	Integrin αvβ6-TGFβ-SOX4 Pathway Drives Immune Evasion in Triple-Negative Breast Cancer.
9/2021	Author Correction: Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.
1/2020	Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling.
1/2020	Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer.
11/2018	Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment.
11/2018	ΔNp63-driven recruitment of myeloid-derived suppressor cells promotes metastasis in triple-negative breast cancer.
1/2017	Crk adaptor protein promotes PD-L1 expression, EMT and immune evasion in a murine model of triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sushil Kumar Research Topics

Disease

117	Neoplasms (Cancer) 03/2024 - 01/2006
31	Neoplasm Metastasis (Metastasis) 03/2024 - 01/2011
22	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022 - 06/2010
20	Infections 09/2023 - 11/2005
13	Inflammation (Inflammations) 11/2021 - 01/2011
12	Hypoxia (Hypoxemia) 01/2023 - 01/2016
12	Adenocarcinoma 12/2022 - 10/2012
12	Breast Neoplasms (Breast Cancer) 01/2022 - 03/2009
9	Carcinogenesis 08/2023 - 08/2012
8	COVID-19 07/2023 - 01/2021
7	Pulmonary Hypertension 11/2023 - 10/2016
7	Triple Negative Breast Neoplasms 11/2021 - 01/2017
7	Neuroblastoma 08/2018 - 09/2011
7	Stomach Neoplasms (Stomach Cancer) 07/2016 - 09/2009
5	Virus Diseases (Viral Diseases) 01/2023 - 12/2015
5	Disease Progression 11/2022 - 12/2015
5	Tuberculosis (Tuberculoses) 01/2021 - 07/2007
4	Pancreatitis 10/2022 - 01/2011
4	Carcinoid Tumor (Carcinoid) 01/2022 - 08/2013
4	Colonic Neoplasms (Colon Cancer) 01/2021 - 07/2014
4	Metaplasia 01/2020 - 10/2011
4	Body Weight (Weight, Body) 01/2016 - 03/2006
3	Diabetes Mellitus 03/2024 - 12/2022
3	Carcinoma (Carcinomatosis) 12/2023 - 10/2018
3	Familial Primary Pulmonary Hypertension 11/2023 - 10/2016
3	Ovarian Neoplasms (Ovarian Cancer) 10/2023 - 01/2011
3	Chronic Pancreatitis 10/2022 - 12/2016
3	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 08/2015
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 01/2016
3	Gastritis 08/2021 - 12/2015
3	Cataract (Cataracts) 08/2021 - 01/2012
3	Tics (Tic) 01/2021 - 08/2019
3	Lung Neoplasms (Lung Cancer) 09/2020 - 01/2017
3	Dyspepsia (Indigestion) 09/2017 - 10/2011
3	Colorectal Neoplasms (Colorectal Cancer) 11/2016 - 01/2014
3	Rhabdomyosarcoma 01/2016 - 09/2011
2	Hyperglycemia 03/2024 - 12/2022
2	Sepsis (Septicemia) 01/2024 - 12/2023
2	Mitochondrial Diseases (Mitochondrial Disease) 11/2023 - 01/2017

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 03/2024 - 11/2009
18	MucinsIBA 12/2022 - 01/2011
14	CytokinesIBA 03/2024 - 01/2011
11	Biomarkers (Surrogate Marker)IBA 12/2022 - 01/2011
10	LigandsIBA 01/2021 - 01/2011
9	EnzymesIBA 11/2022 - 01/2006
9	AntigensIBA 07/2021 - 03/2014
6	AntibodiesIBA 08/2023 - 01/2011
6	RNA (Ribonucleic Acid)IBA 01/2023 - 12/2021
6	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2008
6	Acetazolamide (Diamox)FDA LinkGeneric 01/2022 - 08/2013
6	sulforaphaneIBA 01/2022 - 08/2013
5	Gemcitabine FDA Link 12/2022 - 01/2018
5	Reactive Oxygen Species (Oxygen Radicals)IBA 11/2022 - 11/2018
5	VaccinesIBA 12/2021 - 07/2014
5	InterferonsIBA 09/2021 - 01/2019
5	c-Mer Tyrosine KinaseIBA 01/2021 - 01/2016
5	Phosphotransferases (Kinase)IBA 01/2021 - 09/2014
4	Complement System Proteins (Complement)IBA 01/2023 - 10/2018
4	Immune Checkpoint InhibitorsIBA 11/2022 - 01/2017
4	Topotecan (Hycamtin)FDA LinkGeneric 06/2022 - 09/2011
4	MicroRNAs (MicroRNA)IBA 01/2022 - 06/2010
4	Transcription Factors (Transcription Factor)IBA 01/2020 - 11/2018
4	InterleukinsIBA 11/2018 - 07/2014
3	Histones (Histone)IBA 03/2024 - 11/2013
3	BilirubinIBA 12/2023 - 01/2016
3	Peptides (Polypeptides)IBA 09/2023 - 11/2009
3	Immunoglobulin G (IgG)IBA 08/2023 - 01/2021
3	Interleukin-6 (Interleukin 6)IBA 01/2023 - 01/2017
3	Conditioned Culture MediaIBA 01/2023 - 01/2021
3	ChemokinesIBA 11/2022 - 11/2018
3	pazopanib FDA Link 06/2022 - 09/2011
3	AntioxidantsIBA 05/2022 - 01/2006
3	Lipocalin-2IBA 02/2022 - 09/2020
3	CateninsIBA 01/2022 - 01/2012
3	Mucin 5ACIBA 01/2022 - 01/2021
3	Chemokine ReceptorsIBA 12/2021 - 01/2016
3	CarcinogensIBA 08/2021 - 09/2012
3	ProdrugsIBA 10/2020 - 01/2016
3	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2020 - 03/2009
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 05/2020 - 03/2009
3	Paclitaxel (Taxol)FDA LinkGeneric 05/2020 - 11/2013
3	Grape Seed ExtractIBA 01/2019 - 01/2014
3	Polypropylenes (Polypropylene)IBA 04/2017 - 10/2013
3	tyrosine receptor (receptor, tyrosine)IBA 01/2017 - 09/2014
3	Silybin (Lagosa)IBA 11/2016 - 07/2014
2	Fluorouracil (Carac)FDA LinkGeneric 03/2024 - 03/2006
2	Anti-Bacterial Agents (Antibiotics)IBA 02/2024 - 07/2022
2	FIBSIBA 11/2023 - 10/2016
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2023 - 01/2020
2	PlatinumIBA 10/2023 - 01/2020
2	AutoantigensIBA 10/2023 - 11/2017
2	Oxygen (Dioxygen)IBA 07/2023 - 11/2022

Therapy/Procedure

42	Therapeutics 04/2023 - 03/2009
16	Immunotherapy 11/2022 - 01/2017
11	Drug Therapy (Chemotherapy) 01/2021 - 03/2009
5	Lasers (Laser) 01/2023 - 01/2014
5	Dacryocystorhinostomy 01/2023 - 01/2014
4	Sutures (Suture) 08/2021 - 05/2005
3	Catheters 01/2024 - 11/2005
3	Chemoprevention 06/2018 - 11/2016